Figure 8.

miR-25 Tough Decoy Transfer Shows Anti-fibrotic Properties in SERCA2a KO Mice

(A) Experimental protocol for SERCA2a KO HF mice treated with AAV9 control and miR-25 TuD is depicted. (B) qRT-PCR of miR-25 and fibrosis markers TGF-β, Vimentin, and ColIA2 are shown. In SERCA2a KO TAC mice treated with AAV9 control, both miR-25 and fibrosis markers significantly increase. miR-25 TuD treatment significantly decreases miR-25 and fibrosis markers. (C) Masson trichrome staining of SERCA2a KO TAC mice showed decrease in fibrosis in miR-25 TuD-transferred mice compared to AAV9 control-transferred mice. (D) Western blot shows a decreasing trend of collagen, a significant decrease of α-SMA, and a significant increase of SMAD7 between heart failure mice treated with AAV9 control and AAV9 miR-25 TuD. No significant changes were reported for SERCA2a. All data are represented as means ± SD (*p < 0.05, **p < 0.01, ***p < 0.005). Scale bar, 1 mm.